Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Crizotinib + Filgotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Crizotinib||Xalkori||PF-02341066||ALK Inhibitor 26 MET Inhibitor 53 RON Inhibitor 11 ROS1 Inhibitor 17||Xalkori (crizotinib), inhibits ALK kinase, ALK fusion proteins, c-Met, ROS1 fusion proteins, and MST1R (RON), resulting in growth inhibition of tumor cells (PMID: 26951079, PMID: 22617245). Xalkori (crizotinib) is FDA approved for use in patients with ALK or ROS1 positive (rearrangements and fusions) non-small cell lung cancer, and in pediatric patients 1 year and older and young adults with relapsed or refractory, ALK-positive systemic anaplastic large cell lymphoma (FDA.gov).|
|Filgotinib||GLPG0634||JAK1 Inhibitor 9||Filgotinib (GLPG0634) is a selective JAK1 inhibitor, which may be efficacious in immune-inflammatory diseases (PMID: 24006460, PMID: 28729401).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EML4 - ALK||lung non-small cell carcinoma||predicted - sensitive||Crizotinib + Filgotinib||Preclinical - Cell culture||Actionable||In a preclinical study, non-small cell lung carcinoma cells harboring EML4-ALK in culture that had, over time, acquired resistance to Xalkori (crizotinib) showed decreased drug resistance when treatment was combined with Filgotinib (GLPG0634), demonstrating reduced expression of Osmr and phosphorylated-Stat3, and decreased cell viability (PMID: 28729401).||28729401|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|